Chemically Engineered Peptide Efficiently Blocks Malaria Parasite Entry into Red Blood Cells

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Parasitology

Background:

• Malaria parasite invasion of red blood cells is a critical step in disease pathogenesis.
• Protein-protein interactions, such as between PfAMA1 and PfRON2, are key targets for antimalarial drug development.

Purpose of the Study:

• To engineer a cyclic peptide inhibitor targeting the malaria parasite invasion pathway.
• To enhance the binding affinity and inhibitory potency of a native peptide ligand.

Main Methods:

• Chemical peptide engineering, including residue insertion, backbone cyclization, and disulfide bond formation.
• Surface plasmon resonance (SPR) to quantify binding affinity.
• In-vitro parasite growth inhibition assays.
• Deep learning-based structure prediction (ColabFold-AlphaFold2) for complex structural analysis.

Main Results:

• A unique cyclic peptide was successfully engineered with significantly enhanced affinity (20-fold) for its receptor, PfAMA1, compared to the native ligand PfRON2.
• The engineered peptide demonstrated augmented potency in inhibiting parasite growth in vitro.
• Structural analysis provided insights into the molecular basis of the peptide's enhanced activity.

Conclusions:

• Rational chemical engineering of peptide backbone and side chains is an effective strategy for designing potent peptide-based inhibitors.
• This approach can be utilized to disrupt disease-related protein-protein interactions, offering a novel therapeutic avenue for malaria.
• Engineered cyclic peptides represent a promising class of therapeutics against malaria parasite invasion.